Aromatase inhibitors or blockers are a class of drugs that are used to lower the concentration of estrogen in the blood and increase the levels of one’s own testosterone and gonadotropic hormones. Aromatase blockers are also used to treat and prevent gynecomastia in men.
In bodybuilding, aromatase inhibitors are used most often during an anabolic steroid cycle for:
prevention of gynecomastia
increase in the level of anabolic hormones in the blood
increasing relief (by eliminating the negative effects of estrogen)
prevention of hypertension
reducing estrogen suppression of the hypothalamic-pituitary-testicular axis, leading to faster recovery.
Application on the course
The tactics of most domestic athletes is reduced to the use of aromatase inhibitors when the first signs of gynecomastia appear (swelling, itching in the nipples, redness). However, this approach is not optimal.
The most rational solution is to perform an estradiol analysis after about 10 days of taking anabolic steroids with a short half-life (testosterone propionate, methandrostenolone) or after 3-4 weeks of long ester administration (enanthate, sustanon, cypionate). Then an average dosage of anastrozole 0.5 mg every other day is prescribed. After 10 days, a control analysis of estradiol is performed and the dosage is adjusted according to the results.
A compromise option would be the use of a moderate or low dosage of anastrozole with a focus on subjective sensations. If after the appointment there is a drop in libido, erectile dysfunction, depression, then it is necessary to lower the dose.
As you know, estrogen in moderation is useful even for the male body. Estrogen hormones enhance the sensitivity of androgen receptors and increase the effectiveness of the course, and also have an anabolic and protective effect in themselves.
Inhibition of muscle growth
Arthralgia (joint pain)
Decreased bone strength
Violation of the lipid profile of the blood (increased cholesterol)
Decreased libido and deterioration in general condition
There are no reviews yet.